Gardasil HPV Vaccine Injury Lawsuit 2026: What POTS and Autoimmune Plaintiffs Need to Know

In July 2022, the Judicial Panel on Multidistrict Litigation (JPML) centralized federal Gardasil HPV vaccine injury lawsuits into MDL 3036, transferring cases to the Northern District of California. The move acknowledged what plaintiff attorneys had argued for months: the factual and legal questions across cases were identical — did Merck know about POTS, autoimmune disorders, and premature ovarian failure risks, and did it adequately warn patients and physicians?

This article covers the verified framework of MDL 3036 and the parallel NVICP pathway through the U.S. Court of Federal Claims. For current case counts, bellwether selection schedules, and judge assignments, check PACER directly — MDL dockets move faster than any web article can track.

---

The Gardasil Background: What Changed After 2015

Gardasil received FDA approval in 2006 for females ages 9–26 and was subsequently expanded to males and older adults. By 2015, two patterns were emerging in the adverse-event literature that Merck’s pharmacovigilance teams would have been reviewing:

First, POTS case reports following Gardasil administration began appearing in European pharmacovigilance databases, including the Danish and Norwegian health registries that later prompted formal safety reviews. POTS is not a subtle condition — patients experience a 30+ beat-per-minute heart rate surge upon standing, chronic fatigue, brain fog, and presyncope that often ends competitive academic and athletic careers in teenagers.

Second, premature ovarian insufficiency (POI) reports showed up in young women who had completed the Gardasil series. POI at ages 16–25, absent a genetic explanation, is a significant finding that no prior condition fully explained.

Merck’s internal response to these signals — and whether the prescribing information was updated to reflect them — is the central evidentiary question in MDL 3036 discovery.

---

Legal Theory: Failure to Warn and the Learned Intermediary Doctrine

The Core Failure-to-Warn Claim

Pharmaceutical failure-to-warn claims rest on a straightforward premise: if the manufacturer knew or should have known about a risk, it had an obligation to communicate that risk to prescribers in the package insert, and to patients through the Patient Package Insert (PPI).

Merck’s first-line defense is the learned intermediary doctrine — a majority-rule legal principle that says a drug manufacturer discharges its duty to patients by warning the physician, not the patient directly. If the physician is adequately warned, the manufacturer isn’t liable to the patient.

Gardasil plaintiffs attack this defense on two fronts:

1. Direct-to-Consumer Advertising Exception: Merck ran extensive “One Less” and subsequent campaigns advertising Gardasil directly to teenage girls and parents via television, social media, and printed materials. New Jersey (where Merck is headquartered) and a growing number of states recognize that when a manufacturer bypasses physicians and markets directly to consumers, the learned intermediary doctrine no longer shields them. If a court applies this exception, Merck must show its direct communications adequately warned patients — which plaintiffs argue they did not.

2. Inadequate Warning to Physicians: Even where the learned intermediary doctrine applies, it only works if the physician was actually warned. Plaintiffs allege Merck’s prescribing information systematically downplayed autoimmune and autonomic adverse event signals observed in its own post-marketing surveillance data.

Design Defect: Bruesewitz and What It Actually Forecloses

This is one of the most misunderstood dimensions of Gardasil litigation, and what plaintiffs often miss is that the design defect path through civil court is significantly narrowed.

In Bruesewitz v. Wyeth, 562 U.S. 223 (2011), the Supreme Court held that the National Childhood Vaccine Injury Act of 1986 preempts state-law design defect claims against vaccine manufacturers. The Court’s reading of the statute was that Congress deliberately chose to channel design defect claims through NVICP rather than allow them in tort courts — a tradeoff for the liability protections Congress gave manufacturers to ensure vaccine supply.

What this means for Gardasil cases: plaintiffs cannot sue Merck in MDL 3036 claiming the vaccine was defectively designed under state tort law. The core civil theories in MDL 3036 are failure to warn and, in some formulations, manufacturing defect — not design defect.

A secondary theory in some individual complaints targets Merck’s choice of aluminum phosphate as the adjuvant — the ingredient that amplifies immune response. Plaintiffs’ experts are expected to argue that Gardasil’s adjuvant concentration exceeds that of comparable vaccines and that Merck chose it over alternatives for manufacturing cost reasons. Whether this framing survives as a failure-to-warn argument (Merck failed to warn about adjuvant reactogenicity) rather than a preempted design defect claim is a live issue.

---

Two Legal Pathways: NVICP vs. MDL 3036

My read on how Gardasil plaintiffs should think about this: NVICP and MDL 3036 are not interchangeable alternatives — they are structurally different systems with different proof standards, timelines, and payout structures. Choosing the wrong path, or missing the election window between them, can be fatal to a claim.

NVICP: The Federal No-Fault Compensation System

The National Vaccine Injury Compensation Program (NVICP) was created by the National Childhood Vaccine Injury Act of 1986, codified at 42 U.S.C. §§ 300aa-1 through 300aa-34. Congress established it to provide a swift, no-fault alternative to tort litigation for vaccine injuries — and to protect manufacturers from ruinous liability that was threatening vaccine supply in the 1980s.

How the NVICP process works, step by step:

1. File a petition with the U.S. Court of Federal Claims (42 U.S.C. § 300aa-11). The petition must include the vaccine received, the injury, and medical records supporting the claim.

2. Assignment to a Special Master: The Court of Federal Claims has a dedicated Office of Special Masters who handle VICP petitions. These are not judges but federal officers with specialized expertise in vaccine injury cases. They conduct evidentiary hearings and issue decisions.

3. Table vs. Off-Table: The Vaccine Injury Table (VIT) lists specific vaccines and the injuries/timeframes that automatically establish entitlement — if your injury and timing match, causation is presumed. POTS and most autoimmune conditions following HPV vaccination are not current table injuries, which means a Gardasil petitioner must prove causation through an off-table claim.

4. Off-Table Causation Standard — the Althen Test: For off-table claims, petitioners must satisfy the three-part Althen test: (1) a medical theory causally connecting vaccination and injury; (2) a logical sequence of cause and effect; and (3) a proximate temporal relationship between vaccination and injury. This requires credible expert medical testimony — not just temporal association.

5. Entitlement Hearing: The Special Master holds a hearing, evaluates expert testimony from both petitioner and the government (represented by HHS), and issues a decision on entitlement.

6. Damages Phase: If entitlement is established, compensation is determined under 42 U.S.C. § 300aa-15 — covering all medical expenses, lost earnings (actuarially projected), and pain and suffering up to $250,000.

7. Attorney Fees: This is the NVICP’s most plaintiff-friendly feature. Under § 300aa-15(e), HRSA pays reasonable attorney fees and costs from the Vaccine Injury Compensation Trust Fund — even if the petition is ultimately unsuccessful, provided it was filed in good faith and had a reasonable basis for the claim. This structure means petitioners don’t bear attorney cost risk the way they do in contingency civil litigation.

8. Election After NVICP: If the petitioner is awarded compensation and accepts it, civil remedies are foreclosed. If the petitioner rejects the award, or if the petition is dismissed after a specified period, the petitioner may elect to file a civil suit. The election window is strict — missing it can forfeit the civil option.

MDL 3036: Civil Tort Litigation

MDL 3036 is federal civil litigation — failure to warn, strict product liability, and potentially manufacturing defect — consolidated for pretrial coordination. The proof standard is higher: you must show Merck’s conduct was legally inadequate, not just that you were injured after vaccination. There is no pain-and-suffering cap in civil tort (unlike NVICP’s $250,000 ceiling). Punitive damages are available in states like California and Texas if Merck’s conduct rises to malice or fraud.

The strategic question: For plaintiffs with strong causation evidence, serious permanent injuries, and a fact pattern showing Merck had knowledge it suppressed, MDL 3036 offers the potential for substantially higher compensation than NVICP’s capped structure — but carries higher evidentiary burden and longer timelines.

---

PREP Act Preemption: The Litigation’s Wild Card

Shortly after the COVID-19 pandemic began, HHS expanded PREP Act declarations to cover additional vaccination programs. Merck has argued in some cases that HPV vaccinations administered at healthcare facilities during this period — as part of catch-up immunization during COVID-era well visits — qualify as “covered countermeasures” under the PREP Act, granting Merck near-absolute immunity.

Courts that have addressed this argument have generally rejected it on the grounds that:

• Gardasil is not a COVID-19 countermeasure
• The PREP Act’s public policy purpose — protecting pandemic response products — does not extend to routine vaccination schedules that predate the pandemic by 14 years

However, this argument is not fully resolved at the circuit level. If the Ninth Circuit issues a broad ruling on PREP Act scope, it could affect MDL 3036’s composition significantly. Plaintiffs’ attorneys are tracking this actively.

---

Eligibility Checklist: Do You Have a Claim?

Work through each criterion honestly before investing time:

Criterion	What You Need
Vaccination location	Gardasil or Gardasil 9 administered in the United States
Product	Gardasil (4-valent) or Gardasil 9 (9-valent) — not Cervarix
Injury type	POTS, CRPS, POI/POF, demyelinating disease, documented autoimmune condition
Temporal link	Symptom onset within 24 months of last dose, no prior diagnosis
Medical documentation	Vaccination record + diagnostic records + treating physician records
Pre-vaccination health	Able to demonstrate no prior diagnosis of claimed injury
Statute of limitations	Civil SOL not yet expired; or NVICP 36-month window from first symptom still open

If you meet these criteria, the next question is whether your state’s civil statute of limitations (or the NVICP 36-month window) is still open.

---

Statute of Limitations: State-by-State (Civil Claims)

State	Period	Accrual Rule	Minor Tolling
California	2 years	Discovery rule — from date you knew or should have known	Until age 18, then 2 years
New York	3 years	Discovery rule (CPLR §214-c)	Until age 18, then 3 years
Texas	2 years	Injury date or discovery, whichever is earlier	Until age 18, then 2 years
Florida	2 years	Discovery rule	Until age 18, then 7 years
New Jersey	2 years	Discovery rule	Until age 18, then 2 years
Illinois	2 years	Discovery rule	Until age 18, then 2 years

The discovery rule matters enormously here. If you received Gardasil at 15, developed POTS at 17, but only learned in 2024 that Gardasil might be the cause — in many states, your statute might run from 2024, not from the vaccination date. Fraudulent concealment by Merck, if proven, can toll the statute further.

For NVICP: the clock is 36 months from first symptom under 42 U.S.C. § 300aa-16 — a different and sometimes more forgiving deadline than civil SOL, but one that also requires active monitoring.

Do not assume you’re too late without an attorney’s analysis.

---

Damages: What Gardasil Plaintiffs Can Claim

In MDL 3036 (Civil Tort)

Economic Damages

• Past medical expenses (diagnosis, specialist visits, hospitalization, physical therapy)
• Future medical expenses — POTS is a chronic condition with lifetime management costs; a 22-year-old’s future damages alone can run six figures
• Lost wages and diminished earning capacity — teenagers who developed severe POTS often lose years of education and career development
• Vocational rehabilitation costs

Non-Economic Damages

• Pain and suffering (no statutory cap in most civil tort states)
• Loss of enjoyment of life
• Loss of consortium (for married plaintiffs or their spouses)
• Emotional distress

Punitive Damages Available in states like California and Texas if plaintiffs prove Merck acted with malice, oppression, or fraud — meaning Merck knew of the risk and concealed it. The evidentiary bar is high, and federal preemption arguments complicate recovery.

In NVICP

Under 42 U.S.C. § 300aa-15: all past and future medical and care expenses, lost earning capacity (actuarially projected), pain and suffering capped at $250,000, death benefit of $250,000. No punitive damages. Attorney fees paid separately by HRSA regardless of outcome (for good-faith claims).

---

Three Hypothetical Plaintiff Scenarios

These scenarios are illustrative only — they are not based on real individuals and are not representations of likely outcomes.

Hypothetical Scenario 1: 24-Year-Old Female, California, Civil Claim

Emily, 24, received her third Gardasil 9 dose in January 2022 at age 21 while at a college health center in California. In August 2023, a cardiologist diagnosed her with POTS after 18 months of progressive fatigue, near-fainting episodes, and inability to exercise. She has no prior cardiac history. Her vaccination records are intact at the student health portal.

California civil SOL: Discovery accrues from August 2023 — 2 years runs to August 2025. As of mid-2026, that civil window may have closed. However: (1) a fraudulent concealment argument (if Merck suppressed adverse event data) could toll the civil SOL further; (2) the NVICP window of 36 months from first symptom — if symptoms began in early 2022 — may or may not still be open depending on when Emily can document first onset. Both pathways require immediate attorney consultation, not self-assessment.

Hypothetical Scenario 2: 17-Year-Old Minor, Florida, Minor Tolling

Jordan, 17, received Gardasil at age 14 in 2023 and within 6 months began experiencing CRPS symptoms in her right arm — burning pain, temperature changes, and skin discoloration documented by a pain specialist. Her parents discovered a possible Gardasil connection in early 2025 after reading European pharmacovigilance literature.

Florida minor tolling: Florida’s 2-year civil SOL is tolled until the minor turns 18, then runs 7 years for minors (Florida Statute § 95.11). Jordan has until age 25 to file her civil claim — significantly more runway than an adult plaintiff. The NVICP 36-month window runs from first symptom (2023), making it potentially more urgent. Consulting a vaccine injury attorney now rather than at 18 allows time to gather complete records and assess both pathways.

Hypothetical Scenario 3: 28-Year-Old Male, New York, NVICP vs. Civil Election

Marcus, 28, received Gardasil at age 25 in 2022 as part of an expanded adult vaccination program. He developed an MS-like demyelinating condition in 2023, documented by MRI and a neurologist’s diagnosis of clinically isolated syndrome. His civil claim under New York’s CPLR §214-c runs 3 years from discovery.

Marcus first learned of a potential Gardasil connection in February 2024, placing his civil SOL window through approximately February 2027. He also has an active NVICP option (36 months from first symptom). His attorney’s strategic analysis: demyelinating conditions are not current NVICP table injuries, requiring an off-table Althen causation proof. Given the complexity of neurological expert testimony, the MDL civil track may offer more comprehensive damages — including pain and suffering above the NVICP $250,000 cap — if causation can be proven. The election question (NVICP first vs. civil first) requires legal counsel to navigate.

---

Reader Segmentation: Your Situation, Your Next Step

If you or a family member received Gardasil and developed POTS, CRPS, or an autoimmune condition: Document everything now. Pull vaccination records from healthcare providers (they may be archived after several years). Compile all diagnostic records. Write a symptom timeline with specific dates. Then consult a pharmaceutical MDL attorney — not a general personal injury firm.

If your NVICP claim was denied: A denial by a special master does not automatically end your options. Review the denial basis: was it a causation failure, a procedural issue, or an out-of-Table problem that stronger expert testimony could cure? After a dismissal with prejudice, the election window to pursue civil remedies opens — but it is time-limited. Get an independent evaluation from a civil pharmaceutical litigation attorney.

If your civil statute of limitations is approaching: The single most important action is filing a complaint before the deadline — even if your medical record assembly is incomplete. A short-form complaint preserves your claim; it can be developed after filing. MDL 3036 has a short-form complaint mechanism designed for exactly this purpose. Call an attorney today, not next month.

If you were vaccinated as a minor and are now an adult: Most states toll minor statutes until age 18. Check your state’s tolling period — Florida is 7 years post-majority, most others are 2-3 years. Even if you are now 22 or 25, your window may still be open. Do the calculation with an attorney, not from general internet research.

---

How to Find a Qualified Gardasil Attorney

What to Look For

MDL-specific experience: General personal injury attorneys handle car accidents and slip-and-falls. Pharmaceutical MDL litigation requires understanding Daubert expert challenges, bellwether trial strategy, MDL case management orders, and PSC dynamics. These are different skill sets. Ask specifically how many pharmaceutical MDL cases the attorney has handled.

Plaintiffs’ Steering Committee access: PSC members in MDL 3036 have access to consolidated discovery materials, bellwether scheduling, and MDL-wide strategy sessions. A PSC firm’s clients benefit from resources and intelligence that smaller firms don’t have.

Expert witness roster: A credible autonomic neurologist for POTS cases, an immunologist for autoimmune claims, and a pharmacovigilance expert to analyze Merck’s adverse event data are essential. Ask who the firm’s experts are and whether they have testified in comparable pharmaceutical MDLs.

State bar referral resources: The American Bar Association maintains a directory of state and local lawyer referral services at americanbar.org/groups/legal_services/flh-home/flh-lawyer-referral-services-directory — use that directory to find the certified referral program in your state rather than relying on numbers that may be out of date. For NVICP-specific attorneys, the Vaccine Injured Petitioners Bar Association (VIPBA) maintains a member directory of attorneys who practice before the U.S. Court of Federal Claims.

Questions to Ask in Your Initial Consultation

1. How many Gardasil MDL cases do you currently manage?
2. Are you on the Plaintiffs’ Steering Committee, or do you have a co-counsel relationship with a PSC firm?
3. Who are your POTS and autoimmune expert witnesses?
4. What is your litigation expense policy — advanced by the firm or charged to the client?
5. Have you handled NVICP petitions in addition to civil MDL cases, so you can advise on both pathways?
6. How many pharmaceutical MDL cases have you taken to verdict (not just settled)?

Fee Structure Reality Check

In MDL 3036 civil cases, attorneys work on contingency — typically 33–40% of recovery. No recovery, no fee. Litigation expenses (expert witness fees, depositions, filing costs) may be advanced by the firm or billed to the client separately — always confirm which arrangement applies before signing.

In NVICP cases, attorney fees are paid by HRSA from the Vaccine Injury Compensation Trust Fund under 42 U.S.C. § 300aa-15(e) — separate from any compensation award and paid even if the petition is unsuccessful (for good-faith filings). The statute prohibits attorneys from charging petitioners additional fees beyond what HRSA awards. This makes NVICP attorney representation essentially cost-free to the petitioner.

Red Flags to Avoid

• Promises of specific settlement amounts or guaranteed outcomes
• Upfront fee requests before any recovery
• High-pressure signing tactics during the initial call
• Marketing companies that collect leads and sell them to attorneys (not the same as retaining an attorney)
• Firms advertising primarily through social media lead-generation campaigns with no verifiable MDL trial history
• Anyone claiming a “special” relationship with the MDL judge

---

Mass Tort Context: How Gardasil Fits the Broader Landscape

Gardasil MDL 3036 follows a recognizable pattern that Roundup, talc/asbestos, Vioxx, and 3M Combat Arms earplug litigation established. The key structural elements are identical: consolidated pretrial proceedings, bellwether trial selection, Daubert challenges to expert causation testimony, and eventual global resolution (either via master settlement or remand to home districts).

What the Roundup and talc litigation taught us about pharmaceutical/product MDL strategy:

• Internal documents are pivotal: In Roundup, IARC’s 2015 glyphosate classification was already public. What moved the jury was internal Monsanto communications showing company scientists knew of the debate and worked to influence it. The parallel in Gardasil is whether Merck’s pharmacovigilance records contain similar signals about POTS and autoimmune adverse events.
• Daubert is the choke point: Plaintiffs’ expert witnesses must survive Daubert challenges before bellwether trials. In the 3M earplug MDL, early Daubert rulings shaped the entire litigation arc. In Gardasil, the causation experts linking HPV vaccine components to POTS and autoimmune dysfunction face the same scrutiny.
• Bellwether trials inform global settlement: The results of the first 2-3 trial-ready cases reveal jury appetite for plaintiffs’ claims and the damages range, which drives global settlement negotiations. Following MDL 3036’s bellwether schedule is how attorneys (and plaintiffs) assess realistic outcomes.

Related litigation worth understanding for procedural context:

• Depo-Provera Meningioma Lawsuit MDL 3140 — Failure-to-warn theory in hormonal drug MDL
• Ozempic Gastroparesis Lawsuit MDL 3094 — Manufacturer immunity arguments in GLP-1 MDL
• Tepezza Hearing Loss Lawsuit MDL 3079 — Rare adverse event MDL structure
• Mounjaro Thyroid Cancer Lawsuit 2026 — Emerging GLP-1 class litigation
• Bard PowerPort Catheter Lawsuit — Medical device design defect
• Paragard IUD Breakage Lawsuit — Women’s health product liability
• Hair Relaxer Cancer Lawsuit MDL — Consumer product failure-to-warn
• Investment Fraud Recovery Attorney — Financial harm legal remedies

---

The Bottom Line

MDL 3036 is at a critical juncture. Discovery of Merck’s internal communications about HPV vaccine adverse events — the kind of documents that shifted litigation in the Roundup, Vioxx, and talc cases — is likely either ongoing or recently concluded as of mid-2026. Bellwether trials, if scheduled, will reveal how jurors react to POTS plaintiffs and Merck’s defenses.

My read on the NVICP vs. civil pathway question: for plaintiffs with recent vaccinations and early symptom onset, NVICP should be evaluated first — the no-fault standard is lower, attorney fees are covered regardless of outcome, and the process can be faster than MDL. For plaintiffs with strong internal-document discovery potential and injuries severe enough to exceed NVICP’s $250,000 pain-and-suffering cap, MDL 3036 is the higher-value but higher-risk option.

If you or a family member received Gardasil and developed POTS, premature ovarian failure, or a documented autoimmune condition, the cost of a free initial consultation is zero. The cost of missing your statute of limitations is your case. Make the call before doing the math yourself.